BUZZ-抗炎药物在早期试验中表现良好,Aclaris 公司业绩上升

路透中文
Jan 06
BUZZ-抗炎药物在早期试验中表现良好,Aclaris 公司业绩上升

1月6日 - ** 药物开发商Aclaris Therapeutics ACRS.O股价盘前上涨2.3%至2.71美元

** 该公司称其实验性药物ATI-052在一项早期临床试验中显示出良好的安全性和有效性

** ATI-052 旨在通过阻断炎症信号治疗特应性皮炎(湿疹)和哮喘 - ACRS

** 公司称药物耐受性良好,副作用轻微,如注射部位暂时发红

** ATI-052 可在体内存留 26 天,可每三个月给药一次 - ACRS

** 公司计划今年年初进行概念验证试验;2026 年下半年进行更大规模的中期试验

** 截至上次收盘,ACRS 在过去一年中上涨了约 44

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10